Latest Breaking News On - Meeting of the oncologic drugs advisory committee - Page 1 : comparemela.com

The Benefits Outweigh the Risks: Unpacking the Recent ODAC Decisions in Myeloma

The Benefits Outweigh the Risks: Unpacking the Recent ODAC Decisions in Myeloma
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Sundar jagannathKennethc andersonBristol myers squibbMeeting of the oncologic drugs advisory committeeOncologic drugs advisory committeeOncologic drugs advisory committee meetingDrugs advisory committeeCancer careMyers squibbDrugs advisory committee meeting

ODAC Decisions Confirm Benefit of Ide-Cel and Cilta-Cel in Earlier Line R/R Myeloma Therapy

Kenneth C. Anderson, MD, discusses the recent ODAC decisions for ide-cel and cilta-cel, highlighting clinical trial data supporting the indications.

United statesKennethc andersonOncologic drugs advisory committeeBristol myers squibbMeeting of the oncologic drugs advisory committeeDrugs advisory committeeDana farber cancer instituteDecabtagene vicleucel ide cel abecmaCiltacabtagene autoleucel cilta cel carvykti

Cilta-Cel Allows for Treatment-Free Period in Early R/R Multiple Myeloma

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the significance of the FDA approval of cilta-cel in relapsed/refractory multiple myeloma.

New yorkUnited statesSaadz usmaniOncologic drugs advisory committeeJanssen biotech incMeeting of the oncologic drugs advisory committeeDrugs advisory committeeMyeloma serviceMemorial sloan kettering cancer center

Imetelstat Shows Potential to Transform QOL in Lower-Risk MDS

Sunil Iyer, MD, expands on the potential role of imetelstat for select patients with lower-risk myelodysplastic syndrome.

New yorkUnited statesSunil iyerOncologic drugs advisory committeeMeeting of the oncologic drugs advisory committeeColumbia university irving medical centerInternational prognostic scoring systemDrugs advisory committeeScience summitNew york cityLower risk myelodysplastic syndromePhase 2 3 imerge mds3001 trial nct02598661

FDA Approves Polatuzumab Vedotin Plus R-CHP for Previously Untreated DLBCL

The FDA has approved polatuzumab vedotin-piiq plus rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for certain patients with treatment-naive diffuse large B-cell lymphoma.

Roche polivyOncologic drugs advisory committeeInternational prognostic indexMeeting of the oncologic drugs advisory committeeDrugs advisory committeePacific lymphoma conferencePolatuzumab vedotin piiqDiffuse largeb cell lymphoma